Jim Weiss, founder and chairman of Real Chemistry, and the 2025 HBA Honorable Mentor, discusses the foundation and journey ...

Johnson & Johnson submitted a supplemental Biologics License Application to expand Stelara’s use to children aged two years ...

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

The key to improving SFE in 2025 lies in fundamentally reorienting measurement from representative activities to the value ...

Insights on ways pharmacy benefit managers can tap earned media to enhance their reputation—and demonstrate value through ...

The companies are working together to make it easier for companies to offer health plans that include these medications.

A study by GNC suggests that GLP-1s users are risking malnourishment and muscle loss. GNC announced the results of a study ...

Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...

Transformation in healthcare is ongoing and purpose-driven. It’s not a fleeting trend but a continuous process rooted in ...

While drug discount programs are potentially beneficial in increasing access to necessary medications, in some situations, ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...